Wedbush Reiterates Outperform as Outerwall (OUTR) Looks to Maximize Value
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Roth Capital Upgrades Outerwall Inc. (OUTR) to Neutral
March 15, 2016 8:14 AM EDTRoth Capital upgraded Outerwall Inc. (NASDAQ: OUTR) from Sell to Neutral.
For an analyst ratings summary and ratings history on Outerwall Inc. click here. For more ratings news on Outerwall Inc. click here.
Shares of Outerwall Inc. closed at $34.39 yesterday.
... MoreCurrent Outerwall (OUTR) Multiple Implies No Takeout Premium - B. Riley
March 15, 2016 7:13 AM EDTB. Riley analyst, Eric Wold raised his PT to $50 from $42 after Outerwall's (NASDAQ: OUTR) Board initiated a process to explore both strategic and financial alternatives to boost shareholder value.
Shares of OUTR have declined 47% since management announced plans to return 75-100% of FCF to... More
After-Hours Stock Movers 03/14: (CPXX) (SZYM) (ESI) Higher; (IMMU) (MNKD) (NVIV) Lower (more...)
March 14, 2016 6:09 PM EDTCelator Pharmaceuticals, Inc. (Nasdaq: CPXX) 373% HIGHER; announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.
Solazyme, Inc. (Nasdaq: SZYM) 29.5% HIGHER; has signed a definitive multi-year global supply agreement with Unilever.... More
Outerwall (OUTR) Raises Quarterly Dividend 100% to $0.60; 7% Yield
March 14, 2016 4:08 PM EDTOuterwall (NASDAQ: OUTR) declared a quarterly dividend of $0.60 per share, or $2.4 annualized. This is a 100% increase from the prior dividend of $0.30.
The dividend will be payable on June 21, 2016, to stockholders of record on June 7, 2016, with an ex-dividend date of June 3,... More
Outerwall (OUTR) to Explore Strategic And Financial Alternatives
March 14, 2016 4:06 PM EDTOuterwall Inc. (Nasdaq: OUTR) today announced that its Board of Directors has initiated a process to explore strategic and financial alternatives to maximize shareholder value. Outerwall has retained Morgan Stanley & Co. LLC as its financial advisor, and Perkins Coie LLP as its legal advisor to assist in this process.
In addition, the Company today reaffirmed the Board and management team's commitment to managing Outerwall's businesses for profitability and cash flow and focusing on expense management, operational efficiencies and network optimization, with the... More
